IGF1 and neoplasm: Additionally, metformin has demonstrated systemic effects associated with the suppression of tumor development via the attenuation of insulin/insulin-like growth factor (IGF)-1 signaling, such as decreasing proinflammatory cytokine levels, reducing the expression of cell adhesion molecules, inhibiting the Warburg effect, and causing lactate secretion by tumors [15,16].